Skip to content
A technician using integrated black gloves to handle a glass vial inside a SKAN "spectra" sterility testing isolator.

Grade D, or something else? Clearing up cleanroom grading for isolators

How to build a defensible state of control when the guidance doesn’t say

Learn more

For sterility-testing teams, decisions about cleanroom background environments can carry multi-million-dollar implications. However, global guidance does not provide a single, explicit background-classification requirement for closed sterility-testing isolators. The 2022 revision of EU Annex 1 sharpened expectations around aseptic processing, but also introduced uncertainty around how those expectations apply to sterility-testing laboratories.

For closed sterility-testing isolators, a defensible background selection requires a site-specific justification linking room conditions to isolator performance, material transfers, cleaning and bio-decontamination practices, and reliable microbial recovery. Sterility test results alone do not demonstrate a state of control; the justification must remain supported by the performance of the complete testing system.

This article brings together relevant regulatory guidance and industry practice—including Annex 1, FDA aseptic processing guidance, PIC/S inspectorate network guidance, and the harmonized pharmacopeial sterility-testing chapters—along with real-world Quality Control (QC) experience, to help teams navigate that ambiguity and focus on demonstrating a defensible state of control.

The real cost of a sterility-test failure

  • 1.5x workload

    Investigations can require QC and manufacturing teams, especially deviation management personnel, to work 1.5x their normal load during the first weeks.

  • 15-20 people pulled in

    A single failure often engages 15 to 20 staff, including senior QA, manufacturing leads, microbiologists, EM specialists, and deviation management.

  • 1-3 months of intensive effort

    Most investigations require 1 to 3 months of concentrated work—data gathering, environmental monitoring (EM) trending, investigational testing, documentation, and review cycles. Depending on resource availability and root cause analysis, this can expand up to six months, or in rarer cases a year.

  • Millions at stake

    For biologics and high-value sterile products, a single batch can represent millions in product value if delayed or rejected.

“Contamination during sterility testing doesn’t just risk a batch—it risks the global supply of a life-saving or preventative treatment.”

Zoë Reilly, Senior Technical Expert Sterility Assurance, SKAN

Why the classification of cleanroom environments for sterility testing remains unclear

  • Legacy practice

    Sterility testing predates today’s aseptic manufacturing expectations and was historically performed in minimally controlled spaces.

  • Annex 1 doesn’t cover the test itself

    Annex 1 sets a Grade D background for isolators used to manufacture product. Isolators used to test finished product for sterility serve a different purpose entirely, and Annex 1 never says what background grade they require.

  • FDA leaves it to the site

    FDA’s aseptic-processing guidance expects controls comparable to those used in aseptic filling, but leaves the testing background’s exact grade to be justified by the site itself.

  • Older guidance predates the current rules

    PIC/S PI 014-3 guidance for sterility-testing isolators, which recommends a controlled (but not specifically classified) environment, was written before Annex 1’s 2022 revision, and never reconciled with it.

  • Incomplete international standards for sterility testing

    USP and its harmonized counterparts in Europe and Japan define how to run the sterility test itself, but none of them address the cleanroom background it’s performed in.

  • QC vs manufacturing culture

    Monitoring strategies, behaviors, and operating norms in QC labs have evolved differently from production areas.

Self-check: Document your risk assessment. Are you in control?

  • Inspectors check:
    documented rationale for the selected background, supporting environmental data, and implementation of access, gowning, cleaning, ventilation and material-flow controls.

    Demonstrate control by:
    defining, verifying and documenting the controls behind the selected background within the Contamination Control Strategy, with Quality Unit approval, a named owner, and a defined review cycle—and showing whether it’s formally Grade D qualified or only monitored against Grade D limits.

  • Inspectors check:
    glove and chamber integrity-test methods, frequencies and results; pressure and alarm records; and evidence that routine loading and material transfers follow qualified procedures.

    Demonstrate control by:
    suitable integrity testing at justified intervals, documented pressure and alarm responses, and qualified loading and material transfer procedures.

  • Inspectors check:
    cleaning procedures and records, bio-decontamination validation and requalification, coverage of challenging locations and load configurations, and routine compliance with validated cycle parameters.

    Demonstrate control by:
    effective cleaning, validated bio-decontamination of representative worst-case loads, and routine records confirming operation within established conditions. Requalification should use justified biological challenges, defined acceptance criteria and documented evaluation of any unsuccessful challenge.

  • Inspectors check:
    product-specific method-suitability studies, media sterility and growth-promotion records, adherence to the established test method, and evidence that decontamination agents or inhibitory residues do not compromise microbial recovery.

    Demonstrate control by:
    evidence that sample preparation, decontamination and routine testing preserve the ability to recover microorganisms present in the product.

  • Inspectors check:
    alignment of training with current procedures, operator qualification and competency reassessment, observed aseptic practices, and retraining where investigations identify a training or competency gap.

    Demonstrate control by:
    standardized training materials, harmonizing trainer messaging, routine refreshers, accessible records, and consistent daily execution. Include initial qualification, periodic competency reassessment and observation of actual cleaning, loading, transfer and testing practices.

  • Inspectors check:
    how EM locations/heights were chosen, interpretation of recovery levels and trends, and risk-point prioritization.

    Demonstrate control by:
    a risk-based sampling plan that distinguishes background-room from isolator monitoring, with justified frequency, limits and response actions, and trending data reflecting real conditions. Ensure sampling does not compromise isolator protection and investigate microbial recovery within the aseptic testing zone.

  • Inspectors check:
    negative-control results, sterility-test positives, investigation evidence, and assessment of potentially affected tests or batches.

    Demonstrate control by:
    negative controls showing no growth, documented investigations, and conclusions supported by qualification, monitoring and testing records. Invalidate a positive sterility test only when applicable criteria are met and documented evidence establishes lab error.

  • Inspectors check:
    deviation volume and recurrence, investigation depth, evaluation of contributing process and system factors, and documented CAPA effectiveness.

    Demonstrate control by:
    timely reporting, evidence-based root-cause analysis, proportionate corrective actions and effectiveness checks demonstrating reduced recurrence.

  • Inspectors check:
    representative sample selection, traceability through handoffs, storage and transport conditions, sample integrity, incubation records and result interpretation.

    Demonstrate control by:
    documented sampling and handling procedures, traceable records, justified holding conditions, controlled incubation and reliable recording and review of microbial growth.

  • Inspectors check:
    preventative-maintenance, filter integrity and calibration records, overdue activities, and assessment of equipment defects or out-of-tolerance results.

    Demonstrate control by:
    maintenance completed at defined intervals, suitable filter-integrity testing, current calibration status and documented assessment of issues before equipment returns to service.

The checklist above highlights areas inspectors may examine; the scope depends on the facility, testing process and identified risks.

“Defending your background environment need not feel intimidating provided you have a clear, in-house, data-backed rationale for your setup, procedures, and result—regardless of the lab’s formal grade.”

Zoë Reilly, Senior Technical Expert Sterility Assurance, SKAN

Reach out to our expert team

Speak with SKAN’s sterility-testing experts about strengthening control through a risk-based Contamination Control Strategy.

Back to top